<section style="font-size: 16px;" data-role="outer"> <section style="margin-bottom: 0px; line-height: 1.75em; margin-left: 8px; margin-right: 8px;" data-mpa-powered-by="yiban.io"><span style="font-size: 16px; font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif;">最近這兩天，一則新聞在香港的各個媒體上刷屏了&mdash;&mdash;</span></section> <section style="margin-bottom: 0px; line-height: 1.75em; margin-left: 8px; margin-right: 8px;"><span style="color: #b75941;"><strong><span style="color: #b75941; font-size: 16px; font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif;">理大與香港中文大學(中大)在合作研發(fā)新藥物上取得重大突破，首創(chuàng)了一種可以治療多種與肥胖癥和胰島素抵抗相關(guān)的代謝性疾病(如糖尿病和脂肪肝)的藥物！</span></strong></span></section> <section style="text-align: center; margin-bottom: 8px; margin-left: 0px; margin-right: 0px;"><img class="rich_pages wxw-img js_insertlocalimg" style="max-width: 100%; height: 238px; display: block; margin-left: auto; margin-right: auto;" src="https://editor-user.365editor.com/wechat/99/82/4969882/1684907413703639.png" width="507" height="238" data-ratio="0.46944444444444444" data-s="300,640" data-src="https://editor-user.365editor.com/wechat/99/82/4969882/1684907413703639.png" data-type="png" data-w="1080" /></section> <section style="text-align: center; margin-left: 8px; margin-right: 8px; margin-bottom: 0px;"></section> <section data-mpa-template="t"> <section style="display: flex; justify-content: center; align-items: center; width: 100%; padding: 8px; box-sizing: border-box;" data-mid=""> <section style="display: flex; justify-content: flex-start; align-items: center; flex-direction: column; width: 100%;" data-mid=""> <section style="display: flex; align-items: center; width: 100%; justify-content: space-between;" data-mid=""> <section style="width: 16px; height: 16px; background-color: #ffc55b; border-radius: 6px 0px 0px; margin-left: -3px; margin-bottom: -13px; box-sizing: border-box;" data-mid=""></section> <section style="width: 16px; height: 16px; background-color: #ffc55b; border-radius: 0px 6px 0px 0px; margin-right: -3px; margin-bottom: -13px; box-sizing: border-box;" data-mid=""></section> </section> <section style="background-color: #ffffff; border-radius: 5px; padding: 2px; width: 100%; z-index: 2; box-sizing: border-box; border: 1px solid #243a6d;" data-mid=""> <section style="width: 100%; border-radius: 5px; padding: 14px; box-sizing: border-box; border: 1px dashed #dbd9d9;" data-mid=""> <section style="font-size: 14px; font-family: PingFangSC-Regular, 'PingFang SC'; color: #243a6d; line-height: 1.75em;"><span style="font-size: 16px;">肥胖是全球普遍的健康問題。</span><span style="font-size: 16px;">根據(jù)世界衛(wèi)生組織的統(tǒng)計，僅2016年，在全球成年人中，就有逾19億人屬于&ldquo;超重&rdquo;、6.5億人屬于&ldquo;肥胖&rdquo;，分別占成年人人口的39% 和13%。</span><span style="font-size: 16px;">而在香港，約兩名成年人中，就有一人的體重指標被界定為&ldquo;超重&rdquo;或&ldquo;肥胖&rdquo;。</span></section> </section> </section> <section style="display: flex; align-items: center; width: 100%; justify-content: space-between;" data-mid=""> <section style="width: 16px; height: 16px; background-color: #ffc55b; border-radius: 0px 0px 0px 6px; margin-left: -3px; margin-top: -13px; box-sizing: border-box;" data-mid=""></section> </section> </section> </section> </section> <section style="line-height: 1.75em; margin: 32px 8px 0px;"><span style="font-size: 16px; font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif;">由<strong><span style="font-size: 16px; font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; color: #667595;">理大應(yīng)用生物及化學科技學系教授、盧家驄慈善基金藥物科學教授梁潤松教授</span></strong>和<span style="font-size: 16px; font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; color: #667595;"><strong>中大醫(yī)學院生物醫(yī)學學院副教授沈秀媛教授</strong></span>牽頭研發(fā)的新藥</span><span style="font-size: 16px; font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; color: #b75941;"><strong>ABarginase</strong></span><span style="font-size: 16px; font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif;">，是全球首款通過全新藥理機制&ldquo;消耗精氨酸&rdquo;來治療多種肥胖相關(guān)疾病的單一藥物。ABarginase開辟了一條藥效安全且持久的新路徑&mdash;&mdash;在此之前，為</span><span style="font-size: 16px; font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif;">治療上述這些相互關(guān)聯(lián)的疾病，患者往往需要服用不同的藥物，這會增加患者出現(xiàn)&ldquo;多藥聯(lián)用&rdquo;問題的風險。</span></section> <section style="line-height: 1.75em; margin-left: 8px; margin-right: 8px; margin-bottom: 0px;"></section> <section style="line-height: 1.75em; margin-left: 8px; margin-right: 8px; margin-bottom: 0px;"><span style="font-size: 16px; font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif;">ABarginase具有廣闊的臨床應(yīng)用前景，它的<span style="font-size: 16px; font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; color: #b75941;">適用癥包括糖尿病前期、II 型糖尿病、非酒精性脂肪肝等</span><span style="font-size: 16px; font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; color: #b75941;">多種代謝疾病</span></span><span style="font-size: 16px; font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif;">，且</span><span style="font-size: 16px; font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; color: #b75941;">制藥成本低、效率高</span><span style="font-size: 16px; font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif;">。因此，更多患者可以負擔得起該藥物并從中受惠。</span></section> <p>&nbsp;</p> </section> <p><img style="display: block; margin-left: auto; margin-right: auto;" src="https://editor-user.365editor.com/wechat/99/82/4969882/1684907413340771.png" width="516" height="271" data-ratio="0.525" data-s="300,640" data-src="https://editor-user.365editor.com/wechat/99/82/4969882/1684907413340771.png" data-type="jpeg" data-w="1000" /></p> <section style="font-size: 16px;" data-role="outer"> <p style="text-align: center; margin-left: 8px; margin-right: 8px; margin-bottom: 0px; line-height: 1.5em;"><span style="font-size: 14px; color: #888888;">研究團隊主要成員：理大梁潤松教授(左)、中大沈秀媛教授(右)。</span></p> <p style="margin-bottom: 0px; margin-left: 8px; margin-right: 8px; line-height: 1.75em;">&nbsp;</p> </section> <p><img style="display: block; margin-left: auto; margin-right: auto;" src="https://editor-user.365editor.com/wechat/99/82/4969882/1684907413337026.png" width="520" height="273" data-ratio="0.525" data-s="300,640" data-src="https://editor-user.365editor.com/wechat/99/82/4969882/1684907413337026.png" data-type="jpeg" data-w="1000" /></p> <section style="font-size: 16px;" data-role="outer"> <p style="text-align: center; margin-left: 8px; margin-right: 8px; margin-bottom: 0px; line-height: 1.5em;"><span style="font-size: 14px; color: #888888;">本次研究結(jié)合了理大在蛋白工程與藥物開發(fā)方面的優(yōu)勢，以及中大在肥胖及糖尿病研究方面的領(lǐng)先實力。</span></p> <section data-mpa-template-id="453" data-mpa-category="模板"> <section data-mpa-category="模板" data-mid=""> <section data-mid=""> <section data-mid=""> <section data-mid=""> <section data-mid=""> <section data-mpa-template="t"> <section style="display: flex; justify-content: center; align-items: center; width: 100%; padding: 8px; box-sizing: border-box;" data-mid=""> <section style="display: flex; justify-content: flex-start; align-items: center; flex-direction: column; width: 100%; padding-left: 0px; padding-right: 0px; box-sizing: border-box;" data-mid=""> <section style="display: flex; align-items: center; width: 100%; justify-content: space-between;" data-mid=""> <section style="width: 16px; height: 16px; background-color: #ffc55b; border-radius: 6px 0px 0px; margin-left: -3px; margin-bottom: -13px; box-sizing: border-box;" data-mid=""></section> <section style="width: 16px; height: 16px; background-color: #ffc55b; border-radius: 0px 6px 0px 0px; margin-right: -3px; margin-bottom: -13px; box-sizing: border-box;" data-mid=""></section> </section> <section style="background-color: #ffffff; border-radius: 5px; padding: 2px; width: 100%; z-index: 2; box-sizing: border-box; border: 1px solid #243a6d;" data-mid=""> <section style="width: 100%; border-radius: 5px; padding: 14px; box-sizing: border-box; border: 1px dashed #dbd9d9;" data-mid=""> <section style="font-size: 14px; font-family: PingFangSC-Regular, 'PingFang SC'; color: #243a6d; line-height: 1.75em;"><span style="font-size: 16px;">肥胖不僅會影響人們的體形，更會誘發(fā)糖尿病、非酒精性脂肪肝、心臟病、高血壓、癌癥等多種慢性病。</span></section> <section style="font-size: 14px; font-family: PingFangSC-Regular, 'PingFang SC'; color: #243a6d; line-height: 1.75em;"><br /><span style="font-size: 16px;">理大與中大的研究團隊發(fā)現(xiàn)，當血液中一種半必需氨基酸&ldquo;精氨酸&rdquo;處于低水平時</span><span style="font-size: 14px;">(即&ldquo;精氨酸饑餓&rdquo;狀態(tài))</span><span style="font-size: 16px;">，細胞會抑制脂肪合成、促進脂肪分解并增強對胰島素的敏感度。不過，一般情況下，人體內(nèi)可分解精氨酸的&ldquo;精氨酸酶&rdquo;只有不足30分鐘的循環(huán)半衰期，時間很短。</span></section> </section> </section> <section style="display: flex; align-items: center; width: 100%; justify-content: space-between;" data-mid=""> <section style="width: 16px; height: 16px; background-color: #ffc55b; border-radius: 0px 0px 0px 6px; margin-left: -3px; margin-top: -13px; box-sizing: border-box;" data-mid=""></section> <section style="width: 16px; height: 16px; background-color: #ffc55b; border-radius: 0px 0px 6px; margin-right: -3px; margin-top: -13px; box-sizing: border-box;" data-mid=""></section> </section> </section> </section> </section> </section> </section> </section> </section> </section> </section> <section style="line-height: 1.75em; margin: 0px 8px;"><span style="color: #667595;"><strong><span style="font-size: 16px; font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif;">梁潤松教授</span></strong></span><span style="font-size: 16px; font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif;">介紹：&ldquo;通過采用先進的融合蛋白方法，我們的研究團隊研制出一種長效的重組人類精氨酸酶ABarginase，它含有一個白蛋白結(jié)合域，能夠與血液中穩(wěn)定且充沛的白蛋白結(jié)合，從而可將循環(huán)半衰期延長約200倍。ABarginase具有較強的酶活性，每星期只需注射一個劑量，就足以使血液循環(huán)中的精氨酸保持在低水平，進而達到&lsquo;精氨酸饑餓&rsquo;的狀態(tài)。&rdquo;</span></section> </section> <p><img style="display: block; margin-left: auto; margin-right: auto;" src="https://editor-user.365editor.com/wechat/99/82/4969882/1684907414699994.png" width="491" height="258" data-ratio="0.525" data-s="300,640" data-src="https://editor-user.365editor.com/wechat/99/82/4969882/1684907414699994.png" data-type="jpeg" data-w="1000" /></p> <section style="font-size: 16px;" data-role="outer"> <p>&nbsp;</p> <section style="margin-right: 8px; margin-bottom: 0px; margin-left: 8px; text-align: center; line-height: 1.5em;"><span style="font-size: 14px; color: #888888;">利用三D打印分子模型展示ABarginase、白蛋白與FcRn receptor在細胞表面的相互作用。</span></section> <section data-mpa-template="t"> <section style="display: flex; justify-content: center; align-items: center; width: 100%; padding: 8px; box-sizing: border-box;" data-mid=""> <section style="display: flex; justify-content: flex-start; align-items: center; flex-direction: column; width: 100%;" data-mid=""> <section style="display: flex; align-items: center; width: 100%; justify-content: space-between;" data-mid=""> <section style="width: 16px; height: 16px; background-color: #ffc55b; border-radius: 6px 0px 0px; margin-left: -3px; margin-bottom: -13px; box-sizing: border-box;" data-mid=""></section> <section style="width: 16px; height: 16px; background-color: #ffc55b; border-radius: 0px 6px 0px 0px; margin-right: -3px; margin-bottom: -13px; box-sizing: border-box;" data-mid=""></section> </section> <section style="background-color: #ffffff; border-radius: 5px; padding: 2px; width: 100%; z-index: 2; box-sizing: border-box; border: 1px solid #243a6d;" data-mid=""> <section style="width: 100%; border-radius: 5px; padding: 14px; box-sizing: border-box; border: 1px dashed #dbd9d9;" data-mid=""> <section style="font-size: 14px; font-family: PingFangSC-Regular, 'PingFang SC'; color: #243a6d; line-height: 1.75em;"><span style="font-size: 16px;">研究人員為兩組經(jīng)飲食誘導(dǎo)的肥胖小鼠每周分別注射一次ABarginase和生理鹽水。八周后，相比于注射生理鹽水的對照組，ABarginase組的小鼠在體重、脂肪量、脂肪肝和糖尿病癥狀</span><span style="font-size: 14px;">(如高血糖、胰島素抵抗、葡萄糖耐受不良)</span><span style="font-size: 16px;">等方面均恢復(fù)至正常水平。</span></section> </section> </section> <section style="display: flex; align-items: center; width: 100%; justify-content: space-between;" data-mid=""> <section style="width: 16px; height: 16px; background-color: #ffc55b; border-radius: 0px 0px 0px 6px; margin-left: -3px; margin-top: -13px; box-sizing: border-box;" data-mid=""></section> </section> </section> </section> </section> <p>&nbsp;</p> <p style="line-height: 1.75em; margin: 0px 8px;"><strong><span style="font-size: 16px; font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; color: #667595;">沈秀媛教授</span></strong><span style="font-size: 16px; font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif;">說：&ldquo;ABarginase在臨床前研究階段已經(jīng)展現(xiàn)巨大潛力，有望為治療多種與肥胖、胰島素抵抗、糖尿病等相關(guān)的代謝性疾病提供安全有效的方案。其中，非酒精性脂肪肝至今沒有獲美國食物及藥物管理局認可的藥物，因此ABarginase的研發(fā)對于治療非酒精性脂肪肝尤其意義重大。我們相信，可以治愈這些相關(guān)疾病的單一藥物已經(jīng)研發(fā)出來了。&rdquo;</span></p> <section data-mpa-template="t"> <section style="display: flex; justify-content: center; align-items: center; width: 100%; padding: 8px; box-sizing: border-box;" data-mid=""> <section style="display: flex; justify-content: flex-start; align-items: center; flex-direction: column; width: 100%;" data-mid=""> <section style="display: flex; align-items: center; width: 100%; justify-content: space-between;" data-mid=""> <section style="width: 16px; height: 16px; background-color: #ffc55b; border-radius: 6px 0px 0px; margin-left: -3px; margin-bottom: -13px; box-sizing: border-box;" data-mid=""></section> <section style="width: 16px; height: 16px; background-color: #ffc55b; border-radius: 0px 6px 0px 0px; margin-right: -3px; margin-bottom: -13px; box-sizing: border-box;" data-mid=""></section> </section> <section style="background-color: #ffffff; border-radius: 5px; padding: 2px; width: 100%; z-index: 2; box-sizing: border-box; border: 1px solid #243a6d;" data-mid=""> <section style="width: 100%; border-radius: 5px; padding: 14px; box-sizing: border-box; border: 1px dashed #dbd9d9;" data-mid=""> <section style="font-size: 14px; font-family: PingFangSC-Regular, 'PingFang SC'; color: #243a6d; line-height: 1.75em;"><span style="font-size: 16px;">目前，研究團隊已在多個國家為該新藥申請了專利，并正提升制藥工藝至符合生產(chǎn)質(zhì)量管理規(guī)范(GMP)的品質(zhì)要求，為開展臨床試驗做好準備。</span></section> </section> </section> <section style="display: flex; align-items: center; width: 100%; justify-content: space-between;" data-mid=""> <section style="width: 16px; height: 16px; background-color: #ffc55b; border-radius: 0px 0px 0px 6px; margin-left: -3px; margin-top: -13px; box-sizing: border-box;" data-mid=""></section> <section style="width: 16px; height: 16px; background-color: #ffc55b; border-radius: 0px 0px 6px; margin-right: -3px; margin-top: -13px; box-sizing: border-box;" data-mid=""></section> </section> </section> </section> </section> <section style="line-height: 1.75em; margin: 0px 8px;"><span style="font-size: 16px; font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif;">梁教授和沈教授表示：&ldquo;作為科學家，一直以來，我們都矢志為改善人類褔祉做出貢獻。成功研發(fā)ABarginse可以說是為我們實現(xiàn)理想邁出的重要一步。&rdquo;</span></section> <p style="line-height: 1.75em; margin: 0px 8px; text-align: center;">&nbsp;</p> <p style="margin-left: 8px; margin-right: 8px; margin-bottom: 0px;"><span style="font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px;">在第48屆日內(nèi)瓦國際發(fā)明展中，香港共有兩項發(fā)明獲得最高殊榮大獎，ABarginase就是其中之一，獲頒&ldquo;發(fā)明者協(xié)會國際聯(lián)合會最佳發(fā)明大獎&rdquo;</span><span style="font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px;">。這既是對該款新藥改善患者福祉、提升全球醫(yī)療衛(wèi)生能力的肯定，也是對香港高校之間科研合作水平的國際級認可。</span></p> <p style="margin-left: 8px; margin-right: 8px; margin-bottom: 0px;">&nbsp;</p> <p style="margin-left: 8px; margin-right: 8px; margin-bottom: 0px;"><span style="font-family: 'Helvetica Neue', Helvetica, 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px;">本研究得到盧家驄慈善基金有限公司、香港特區(qū)政府醫(yī)務(wù)衛(wèi)生局醫(yī)療衛(wèi)生研究基金，以及理大化學生物學及藥物研發(fā)國家重點實驗室支持。</span></p> <p style="margin-left: 8px; margin-right: 8px; margin-bottom: 0px;">&nbsp;</p> </section> <p><img style="display: block; margin-left: auto; margin-right: auto;" src="https://editor-user.365editor.com/wechat/99/82/4969882/1684907414671190.png" width="438" height="230" data-ratio="0.525" data-s="300,640" data-src="https://editor-user.365editor.com/wechat/99/82/4969882/1684907414671190.png" data-type="jpeg" data-w="1000" /></p> <section style="font-size: 16px;" data-role="outer"> <p style="margin-right: 8px; margin-left: 8px; text-align: center; line-height: 1.5em; margin-bottom: 0px;"><span style="font-size: 14px; color: #888888;">盧家驄慈善基金有限公司董事盧伯韶先生(右四)、羅麗珊女士(右三)，研究團隊主要成員梁潤松教授(左三)、沈秀媛教授(左四)，理大應(yīng)用生物及化學科技學系助理教授(研究)李文淵博士(左一)，中大研究及知識轉(zhuǎn)移服務(wù)處處長徐仲鍈教授(右二)，理大知識轉(zhuǎn)移及創(chuàng)業(yè)總監(jiān)王家達先生(左二)，中大研究及知識轉(zhuǎn)移服務(wù)處知識轉(zhuǎn)移活動經(jīng)理文志偉博士(右一)出席發(fā)布會。</span></p> <p style="display: none;">&nbsp;</p> </section>